Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY 4,829.00
+32.00 (0.67%)
At close: Mar 13, 2026
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
74.03M JPY
Profits / Employee
3.92M JPY
Market Cap
1.36T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Toho Holdings | 7,609 |
| Shionogi & | 4,955 |
| Towa Pharmaceutical | 4,788 |
| Tsumura & Co. | 4,272 |
| Sumitomo Pharma | 3,832 |
| Sawai Group Holdings | 3,310 |
| Hisamitsu Pharmaceutical Co. | 2,799 |
Eisai News
- 4 weeks ago - Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - PRNewsWire
- 5 weeks ago - Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters
- 3 months ago - Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript - Seeking Alpha
- 3 months ago - Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - PRNewsWire
- 3 months ago - Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 - PRNewsWire
- 4 months ago - Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - PRNewsWire
- 4 months ago - Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript - Seeking Alpha